Freedom Capital Markets Maintains Buy on Nutex Health, Raises Price Target to $306

Benzinga Newsdesk www.benzinga.com Positive 76.2%

Neg 0% Neu 0% Pos 76.2%

Freedom Capital Markets analyst Gene Mannheimer maintains Nutex Health (NASDAQ:NUTX) with a Buy and raises the price target from $280 to $306.